pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE is a pharma organization headquartered in Mainz, DE. Primary therapeutic focus areas include Non-small Cell Lung Cancer, Solid Tumors, Melanoma (Stage III and IV), Endometrial cancer, Resected (R0 or R1) panc
An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE HQ
2008 Founded
5,119 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
Dose escalation trial of BNT152+153 in patients with cancer
Phase 1 · other · Various solid tumors that are metastatic or unresectable
Dose escalation trial of BNT152+153 in patients with cancer for Various solid tumors that are metastatic or unresectable is a Phase 1 program (other) at BioNTech SE with 1 ClinicalTrials.gov record(s).
Internal code BNT152-01C
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- BioNTech SE
- Phase
- Phase 1
- Modality
- other
- Indication
- Various solid tumors that are metastatic or unresectable
- Status
- active
- Trials
- 1